

# BIO-TECHNE CORP.

ISIN: US09073M1045 WKN: 09073M104 Asset Class: Stock

## Company

2024/06/28 22:00:00

biotechne®

Price

**71.65**

USD

Difference

**-0.24% (-0.17)**



## Contact Details

BIO-TECHNE CORP.

Tel: +1-612-379-8854

--

Fax: +1-612-656-4400

614 McKinley Place North  
East

Web: <http://www.biotechne.com>

55413-2610 Minneapolis

E-mail: [info@bio-techne.com](mailto:info@bio-techne.com)

## Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

## Financial figures, Fiscal year: from 01.07. to 30.06.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	621,482,000		605,556,000		510,606,000	
<b>Common stock capital</b>		1,576,000		392,000		390,000
<b>Fixed assets</b>	2,112,233,000		1,765,472,000		1,839,234,000	
<b>Equity capital of a company</b>		1,966,516,000		1,701,011,000		1,571,234,000
<b>Cash and cash equivalents</b>	180,571,000		172,567,000		199,091,000	
<b>Accrued liabilities</b>		0		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		128,509,000		176,018,000		152,284,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		638,690,000		493,999,000		626,322,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		10,919,000		17,239,000		49,862,000
<b>Total assets</b>	2,733,715,000	2,733,715,000	2,371,028,000	2,371,028,000	2,349,840,000	2,349,840,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	3,050	3,000	2,600
<b>Equity ratio</b>	71.94%	71.71%	67.22%
<b>Debt-equity ratio</b>	39.01%	39.45%	48.77%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	15.71%	12.70%	5.80%

# BIO-TECHNE CORP.

ISIN: US09073M1045 WKN: 09073M104 Asset Class: Stock

## Income statement

	2023	2022	2021
<b>Turnover</b>	1,136,702,000	1,105,599,000	931,032,000
<b>Net income</b>	285,193,000	271,930,000	140,324,000
<b>EBIT</b>	327,662,279	298,012,109	159,423,973
<b>Operating income before taxes</b>	338,659,000	301,386,000	148,175,000
<b>Cash Flow</b>	254,393,000	325,272,000	352,164,000
<b>Net interest income</b>	-11,258,000	-16,867,000	-22,077,000
<b>Research and development expenses</b>	92,493,000	87,140,000	70,603,000
<b>Income taxes</b>	53,217,000	38,287,000	8,590,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	348,986	345,094	335,315

## Board of Directors

## Members of Management Board

Robert Baumgartner	Chairman of Board of Directors
Alpna Seth	Member of Board of Directors
Joseph Keegan	Member of Board of Directors
Judith Klimovsky	Member of Board of Directors
Randolph Steer	Member of Board of Directors
Roeland Nusse	Member of Board of Directors
Rupert Vessey	Member of Board of Directors
John Higgins	Member of Board of Directors
Julie Bushman	Member of Board of Directors
Charles Kummeth	Chairman of Managing Board
Brenda S. Everson	Member of Executive Committee
Jim Hippel	Member of Executive Committee
Kevin Smyth	Member of Executive Committee